On the stock market since 2021, it operates in the world of health and science. It has 220 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 22% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 30% a year on average.
Sales run at $100.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 33 buys and 19 sells. Management buying with its own money is usually read as a good sign.
A loss of $21.5M against $100.0M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 38/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 48/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, NPCE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NPCE is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (51/100) says the stock isn’t cheap.